209 related articles for article (PubMed ID: 36741711)
1. Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer.
Wasamoto S; Imai H; Tsuda T; Nagai Y; Minemura H; Yamada Y; Umeda Y; Kishikawa T; Shiono A; Kozu Y; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Minato K; Kagamu H
Front Oncol; 2022; 12():1080729. PubMed ID: 36741711
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.
Reck M; Mok TSK; Mansfield A; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair M; Garassino MC; de Castro Junior G; Bischoff H; Lam S; Cardona A; Morris S; Liu SV
J Thorac Oncol; 2022 Sep; 17(9):1122-1129. PubMed ID: 35764236
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.
Kutlu Y; Aydin SG; Bilici A; Oven BB; Olmez OF; Acikgoz O; Hamdard J
Medicine (Baltimore); 2023 Apr; 102(15):e33432. PubMed ID: 37058061
[TBL] [Abstract][Full Text] [Related]
6. Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K; Imai H; Wasamoto S; Tsuda T; Minemura H; Nagai Y; Yamada Y; Kishikawa T; Umeda Y; Shiono A; Takechi H; Shiihara J; Kaira K; Kanazawa K; Taniguchi H; Kaburagi T; Kagamu H; Minato K
Thorac Cancer; 2022 Oct; 13(19):2776-2785. PubMed ID: 36062426
[TBL] [Abstract][Full Text] [Related]
7. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma: A systematic review and network meta-analysis.
Du J; Wang X; Fan L; Shan X; Li M; Liu L
Heliyon; 2023 Apr; 9(4):e14794. PubMed ID: 37095958
[TBL] [Abstract][Full Text] [Related]
9. Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Shiono A; Imai H; Wasamoto S; Tsuda T; Nagai Y; Minemura H; Yamada Y; Kishikawa T; Umeda Y; Takechi H; Yamaguchi O; Mouri A; Kaira K; Taniguchi H; Minato K; Kagamu H
Cancer Med; 2023 Jan; 12(1):73-83. PubMed ID: 35699088
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide.
Liu SV; Mok TSK; Nabet BY; Mansfield AS; De Boer R; Losonczy G; Sugawara S; Dziadziuszko R; Krzakowski M; Smolin A; Hochmair MJ; Garassino MC; Gay CM; Heymach JV; Byers LA; Lam S; Cardona A; Morris S; Adler L; Shames DS; Reck M
Lung Cancer; 2023 Dec; 186():107418. PubMed ID: 37931445
[TBL] [Abstract][Full Text] [Related]
11. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.
Zhang C; Huo Y; Shang X; Zhang T; Tang N; Wang H
Respir Res; 2024 Jun; 25(1):253. PubMed ID: 38902698
[TBL] [Abstract][Full Text] [Related]
12. The Glasgow Prognostic Score Predicts Survival Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer.
Igawa S; Yamamoto H; Yamada K; Akazawa Y; Manaka H; Yagami Y; Nakahara Y; Sato T; Mitsufuji H; Sasaki J; Naoki K
Oncology; 2023; 101(11):695-704. PubMed ID: 37494886
[TBL] [Abstract][Full Text] [Related]
13. The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer.
Kasajima M; Igawa S; Manaka H; Yamada K; Akazawa Y; Manabe H; Yagami Y; Yamamoto H; Ito H; Kaizuka N; Nakahara Y; Sato T; Mitshufuji H; Yokoba M; Kubota M; Sasaki J; Naoki K
Oncology; 2023; 101(1):69-76. PubMed ID: 36103811
[TBL] [Abstract][Full Text] [Related]
14. Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer.
Kim SH; Jo EJ; Mok J; Lee K; Kim KU; Park HK; Lee MK; Eom JS; Kim MH
Korean J Intern Med; 2023 Mar; 38(2):218-225. PubMed ID: 36800677
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer.
Imai H; Nagai Y; Minemura H; Tsuda T; Yamada Y; Wasamoto S; Kishikawa T; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Kanazawa K; Taniguchi H; Minato K; Kagamu H
Invest New Drugs; 2022 Oct; 40(5):1066-1079. PubMed ID: 35749041
[TBL] [Abstract][Full Text] [Related]
16. Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer.
Tsuda T; Imai H; Nagai Y; Umeda Y; Shiono A; Shiihara J; Yamaguchi O; Mouri A; Kaira K; Ishizuka T; Taniguchi H; Kagamu H
Oncol Lett; 2023 Mar; 25(3):111. PubMed ID: 36817046
[TBL] [Abstract][Full Text] [Related]
17. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
18. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.
Ishii H; Azuma K; Kawahara A; Matsuo N; Tokito T; Hoshino T
Invest New Drugs; 2021 Feb; 39(1):269-271. PubMed ID: 32783090
[TBL] [Abstract][Full Text] [Related]
19. Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.
Imai H; Wasamoto S; Tsuda T; Nagai Y; Kishikawa T; Masubuchi K; Osaki T; Miura Y; Umeda Y; Ono A; Minemura H; Yamada Y; Nakagawa J; Kozu Y; Taniguchi H; Ohta H; Kasai T; Kaira K; Kagamu H
Thorac Cancer; 2023 Sep; 14(25):2567-2578. PubMed ID: 37469246
[TBL] [Abstract][Full Text] [Related]
20. The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.
Choi MG; Kim YJ; Lee JC; Ji W; Oh IJ; Lee SY; Yoon SH; Lee SY; Lee JE; Kim EY; Choi CM
Cancer Res Treat; 2024 Apr; 56(2):422-429. PubMed ID: 37871898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
